Last reviewed · How we verify
Moxam (latamoxef)
At a glance
| Generic name | latamoxef |
|---|---|
| Sponsor | Eli Lilly |
| Drug class | latamoxef |
| Target | Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Antibiotic Therapy for Early Onset Neonatal Sepsis
- Population Pharmacokinetics of Anti-infective Drugs in Children With Infectious Diseases
- Population Pharmacokinetics of Cephalosporins and Macrolides in Chinese Children With Community Acquired Pneumonia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Moxam CI brief — competitive landscape report
- Moxam updates RSS · CI watch RSS
- Eli Lilly portfolio CI